Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)
Sponsor: Chinese SLE Treatment And Research Group
Summary
This study is a prospective, open-labelled, randomized, controlled, single-center clinical trial. The aim of this study is to investigate the remission rate of patients treated with Telitacicept combined with Rituximab in remission-induction and Telitacicept alone in remission-maintain treatment.
Official title: A Prospective, Randomized, Single-blinded Placebo-controlled, Single Center Clinical Study of the Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2023-06-29
Completion Date
2026-12-31
Last Updated
2023-07-27
Healthy Volunteers
No
Conditions
Interventions
Telitacicept
Patient will be treated with Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months
Placebo of Telitacicept
Patient will be treated with placebo of Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months
Locations (1)
Peking Union Medical College Hospital
Beijing, China